Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Symptomatic Subjects With Generalized Myasthenia Gravis

NCT02473952 is registered in ClinicalTrials.gov with Grifols Therapeutics LLC as lead sponsor.

NCT NCT02473952
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02473952 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Symptomatic Subjects With Generalized Myasthenia Gravis
Lead sponsor
Grifols Therapeutics LLC
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2015
Completion date
January 31, 2018
Enrollment
62 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

myasthenia gravis, generalized